Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 237, Issue 12, 1999, Pages 952-961

  Joussen, Antonia M ^a,c   Germann, Tieno ^b   Kirchhof, Bernd ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b GRÜNENTHAL GMBH   (Germany)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,6 DIOXO 3 PIPERIDINYL)PHTHALIMIDINE; BASIC FIBROBLAST GROWTH FACTOR; SUPIDIMIDE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; TERATOGENICITY;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; CAPILLARIES; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; LYMPHOKINES; PROTEIN ISOFORMS; RABBITS; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033390282     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004170050330     Document Type: Article

References (33)

1. Ausprunk DH, Folkman J (1977) Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14: 53-65
2. Bauer KS, Dixon SC, Figg WD (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Clin Pharmacol 55: 1827-1834
3. Becker MD, Kruse FE, Joussen AM, Rohrschneider K, Nobiling R, Gebhard MM, Völcker HE (1998) In vivo fluorescence microscopy of corneal neovascularisation. Graefe's Arch Clin Exp Ophthalmol 236: 390-398
4. Benelli U, Bocci G, Danesi R, Lepri A, Bernardini N, Bianchi F, Lupetti M, Dolfi A, Campagni A, Agen C, Nardi M, Del Tacca M (1998) The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularisation. Exp Eye Res 67: 133-142
5. Bocci G, Danesi R, Benelli U, Innocenti F, Di Paolo A, Fogli S, Del Tacca M (1999) Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Cancer Chemother Pharmacol 43: 205-212
6. Burr LPH (1992) Intusseptive macrovascular growth: a new mechanism of capillary network formation on angiogenesis. In: Steiner R, Wiesse PB, Langer R (eds) Key principles of science, technology, medicine. Birkhauser, Basel, pp 393-400
7. Cao Y, Linden P, Shima D, Browne F, Folkman J (1996) In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest 98: 2507-2511
8. Casey R, Li WW (1997) Factors controlling ocular angiogenesis. Am J Ophthalmol 124: 521-5299
9. Crum R, Szabo S, Folkman J (1985) A new class of steroids inhibits angiogenesis in the presence of heparin or heparin fragment. Science 230: 1375-1378
10. D'Amato RJ, Loughnan MS, Flynn E, Folkmann J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 91: 4082-4085
11. Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, Basolo F, Campagni A, Tacca MD (1997) Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 3: 265-272
12. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I (1988) A heparin-binding angiogenic protein bFGF is stored within basement membrane. Am J Pathol 130: 393-400
13. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, Schweigerer L (1993) Genistein, a dietary-derived inhibitor of in vitro angioaenesis. Proc Natl Acad Sci USA 90: 2690-2694
14. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA (1995) Inhibition of two angiogenic pathways by distinct alpha integrins. Science 270: 1500-1502
15. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, Cheresh DA (1996) Involvement of integrins alpha v beta 3 and alpha 5 beta 5 in ocular neovascular disease. Proc Natl Acad Sci USA 93: 9764-9769
16. Fung WE (1991) Interferon alpha-2a for treatment of ARMD (letter). Am J Ophthalmol 112: 349-350
17. Geitz H, Handt S, Zwingenberger K (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31: 213-221
18. Hanneken A, de Juan E Jr, Lutty GA, Fox GM, Schiffer S, Hjelmeland LM (1991) Altered distribution of basic fibroblast growth factor in diabetic retinopathy. Arch Ophthalmol 109: 1005-1011
19. Helm F-C, Frankus E, Friderichs E, Graudums I, Flohe L (1981) Comparative teratological investigation of compounds structurally and pharmacologically related to thalidomide. Drug Res 31: 941-949
20. Joussen AM, Kruse FE, Völcker HE, Kirchhof B (1999) Topical application of methotrexate for inhibition of corneal neovascularisation. Graefe's Arch Clin Exp Ophthalmol (in press)
21. Kenyon BM, Browne F, D'Amato RJ (1997) Effects of thalidomide and related metabolites in a mouse model of corneal neovascularisation. Exp Eye Res 64: 971-978
22. Kohler F, Ockenfels H (1970) Teratogene Wirkung der N-phthalyl-DL-glutaminsäure nach intraperitonealer Applikation bei der Maus. Experientia 26: 1157-1158
23. Kruse FE, Joussen AM, Fotsis T, Schweigerer L, Rohrschneider K, Völcker HE (1997) Diätetische Beeinflussung cornealer Neovaskularisationen am Beispiel der Isoflavonoide. Ophthalmologe 94: 152-156
24. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE (1998) Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefe's Arch Clin Exp Ophthalmol 236: 461-466
25. Lenz W (1961) Discussion during Meeting "Rheinisch Westfälischer Kinderärzte", Düsseldorf, Germany 19 November
26. McBride WG (1961) Thalidomide and congenital abnormalities. Lancet 2: 1358
27. Neubert R, Nogueira AC, Neubert D (1993) Thalidomide derivatives and the immune system. 1. Changes in the pattern of integrin receptors and other suface markers on T lymphocyte subpopulations of marmoset blood. Arch Toxicol 67: 1-17
28. Neubert R, Hinz N, Thiel R, Neubert D (1996) Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci 58: 295-316
29. Pasi A, Qu B, Messiha FS (1993) Classifying cytostatics on the basis of their angiocidal and angiostatic effects. J Med 24: 289-300
30. Sampaio EP, Sarno EN, Galilly R, Chon ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173: 699-703
31. Schumacher H, Smith RL, Williams RT (1965) The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br J Pharmacol 25: 324-337
32. Sheu JR, Yen MH, Hung WC, Chang PT, Luk HN (1997) Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha(v) beta 3 integrin monoclonal antibody. Biochim Biophys Acta 1336: 445-454
33. Thomas K (1996) Vascular endothelial growth factor, a potent and selective antiangiogenic agent. J Biol Chem 271: 603-606